Israeli biotech company begins trial for cancer immuno-oncology solution

Written By Mukul Verma

The company’s product, NTX1088, blocks the harmful overexpression of PVR proteins, which occurs in tumors caused by lung, breast, throat and other cancers.

Mukul Verma
Previous

Cancer Focus Fund Invests $5 Million to Support Human Trial of ISA's Immunotherapy to treat Uveal Melanoma
Next

Nectin Announces Extended Series A Financing to Over $25M and Start of Patient Dosing in Phase 1 Clinical Trial of First-in-Class Immunotherapy for Treatment of Patients with Advanced Solid Tumors